secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001104659-25-111940
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports Q3 net loss $2.0M; APOLLO study shows 66% ORR, 50% CR in NHL
--------------------------------------------------------------------------------

- Cash $17.6M + restricted $1.4M; runway into Q3 2026; raised ~$10M via ATM.
- Net loss $2.0M (improved from $2.3M YoY); R&D $2.3M (down from $3.5M).
- APOLLO study: 66% ORR, 50% CR in 12 relapsed NHL patients; durable responses (≥6 months in 5); dose expansion ongoing.
- First patient dosed in OTS RAPID study (MT-401) for AML/MDS; cGMP manufacturing pact with Cellipont.
- Appointed Kathryn Penkus Corzo to Board; two ASH presentations scheduled Dec 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/0001104659-25-111940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465925111940/tm2530894d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-111940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer